NEW YORK, Oct. 2 - Celera Diagnostics today said it has signed a pair of collaborations with Quest Diagnostics and Laboratory Corporation of America to determine the "clinical utility" of lab tests for a variety of diseases.
Terms of the deal call for Quest to receive exclusive yet temporary access to markers with potential clinical usefulness in cardiovascular disease and diabetes. LabCorp gets that deal but only for Alzheimer's disease and breast and prostate cancer.
In exchange, Celera Diagnostics, which will run the disease association studies for the collaboration in-house, said it will become "a preferred vendor" to both clinical diagnostics powerhouses.
Click here for more information on the LabCorp deal, and here for the Quest deal.